Cellectis S.A. (CLLS) Stock: Price, Forecast & Analyst Target
Cellectis S.A. (CLLS) — price $1.03 (-2.83%), as of the Nov 18, 2026 trading session; market cap $104M.
Educational signal · not a buy or sell recommendation · How to read this
Cellectis S.A. · CLLS · NASDAQ
Cellectis S.A. is a clinical-stage biotechnology company focused on developing innovative immuno-oncology products using gene-edited T-cells. The company aims to target and eradicate cancer cells, positioning itself as a leader in the field of cell therapy.
Price as of Nov 18, 2026
Key Statistics
Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $1.03 | |
| Change on the day | -2.83% | |
| 52-week range | $0.8808 – $5.45 | |
| Market capitalisation | $104M | — |
| Shares traded on the day | 6.0K |
Price & events
Other perspectives
Council score for Cellectis (CLLS): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Legends Council
5 lenses, 5 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 20, 2026
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Nov 18, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Cellectis (CLLS), and what does it report?
Short answer
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Cellectis S.A. (CLLS) is listed on NASDAQ. It employs 229 people and is led by Andre Choulika. The market values it at $104M.
What do the latest results show for Cellectis (CLLS)?
Short answer · as of
Against analyst estimates the company has EPS beat 0 of the last 4 reports.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Sep 2025 | $35M | $589,000 | $0.01 (diluted) |
| Q4 FY2025 | $10M | -$26M | -$0.26 (diluted) |
| Q1 FY2026 | $6M | -$18M | -$0.18 (diluted) |
| Q2 FY2026 | $5M | -$22M | -$0.22 (diluted) |
What are the financial strengths and risks for Cellectis (CLLS)?
Short answer · as of
The distress and quality screens read Altman Z -3.96 · Piotroski F 3. Trailing ratios: ROE -94.1% · ROA -24.4% · current ratio 1.37 · earnings yield -58.9% · free-cash-flow yield -55.1%.
Data-derived red flags
- Financial-distress signal — its Altman Z-Score of -3.96 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-94.1%) — the business is not currently generating profit on shareholder capital.
- Inconsistent delivery — missed Wall Street EPS estimates in 2 of the last 4 reported quarters.
What should you watch next at Cellectis (CLLS)?
Short answer · as of
Current published price targets run low $1.30 · high $3.00 · consensus $2.15 · median $2.15 against a quoted price of $1.03 (as of Nov 18, 2026).
What the records here don't tell us
- No forward revenue or earnings estimate is on file.
- The next earnings date is not yet scheduled in the calendar we read.
- No insider Form 4 transaction falls inside the window this page reads.
Checked against the records this page reads, on the dates shown above.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $1.30 – $3.00
- Consensus target
- $2.15
- Median target
- $2.15
Consensus record · Captured .
Measured against a quoted price of $1.03 (as of Nov 18, 2026).
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held CLLS in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported CLLS in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Cellectis (CLLS)?
Investor Questions: CLLS Stock
These answers are editorial: 1 of these 8 answers is drawn from the CLLS research dossier (written Jun 14, 2026 by gpt-4o-mini); the other 7 are question templates that restate figures shown above. Figures in this section are not part of the source register.
Is CLLS a good stock to buy?
Stock Expert AI does not rate CLLS buy, sell or hold. Cellectis S.A. has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the CLLS stock price today?
The last price recorded for Cellectis S.A. (CLLS), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the CLLS price target?
The analyst consensus price target for Cellectis S.A. (CLLS), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
How does Cellectis S.A. navigate regulatory approval processes?
Cellectis S.A. actively engages with regulatory agencies such as the FDA and EMA to ensure compliance with clinical trial requirements and facilitate the approval process for its therapies.
What are the key factors to evaluate for CLLS?
Evaluate CLLS on fundamentals, analyst consensus, and risk factors. To weigh it, read the analyst view under Analyst targets & estimates on this page. No dividend yield as the company reinvests in R&D to advance its product pipeline. Not financial advice.
How frequently does CLLS data refresh on this page?
CLLS's price is the last quote we recorded, from the Nov 18, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven CLLS's recent stock price performance?
Cellectis S.A. (CLLS) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative gene-editing technology that enhances T-cell therapy efficacy. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider CLLS overvalued or undervalued right now?
Cellectis S.A. (CLLS) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Its analyst consensus target is listed under Analyst targets & estimates on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Machine-generated analysis by Stock Expert AI — model gpt-4o-mini, generated Jun 14, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 15 figures on this page — 9 from Financial Modeling Prep (FMP) and 6 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com